Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis

Hammamy, 2018, Sclerotic bone metastasis in pulmonary adenocarcinoma, Case Rep. Med, 2018 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Esposito, 2018, The biology of bone metastasis, Cold Spring Harb. Perspect. Med., 8, 10.1101/cshperspect.a031252 Wu, 2020, Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer, J. Int. Med. Res., 48 Takahara, 2020, A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis, Respir. Med. Case Rep, 30 Digumarthy, 2020, Computed tomography imaging features and distribution of metastases in ROS1-rearranged non–small-cell lung cancer, Clin. Lung Cancer, 21, 153, 10.1016/j.cllc.2019.10.006 Travis, 2015, The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, J. Thorac. Oncol, 10, 1243, 10.1097/JTO.0000000000000630 Takeuchi, 2012, RET, ROS1 and ALK fusions in lung cancer, Nat. Med., 18, 378, 10.1038/nm.2658 Yoshida, 2013, ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases, Am. J. Surg. Pathol., 37, 554, 10.1097/PAS.0b013e3182758fe6 Yin, 2005, Mechanisms of cancer metastasis to the bone, Cell Res., 15, 57, 10.1038/sj.cr.7290266 Yoneda, 2015, Acidic microenvironment and bone pain in cancer-colonized bone, Bonekey Rep, 4, 690, 10.1038/bonekey.2015.58 Mercadante, 1997, Malignant bone pain: pathophysiology and treatment, Pain, 69, 1, 10.1016/S0304-3959(96)03267-8 Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J. Clin. Oncol., 30, 863, 10.1200/JCO.2011.35.6345 Wu, 2018, Phase II study of crizotinib in east Asian patients with ROS1-positive advanced non-small-cell lung cancer, J. Clin. Oncol., 36, 1405, 10.1200/JCO.2017.75.5587 Yoon, 2015, Decoding tumor phenotypes for ALK, ROS1, and RET fusions in lung adenocarcinoma using a radiomics approach, Medicine (Baltimore), 94, e1753, 10.1097/MD.0000000000001753 Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J. Clin. Oncol., 27, 4247, 10.1200/JCO.2009.22.6993 Saito, 2016, Gene aberrations for precision medicine against lung adenocarcinoma, Cancer Sci., 107, 713, 10.1111/cas.12941 Digumarthy, 2020, Imaging features and patterns of metastasis in non-small cell lung cancer with RET rearrangements, Cancers (Basel), 17, 693, 10.3390/cancers12030693 Siravegna, 2017, Integrating liquid biopsies into the management of cancer, Nat. Rev. Clin. Oncol., 14, 531, 10.1038/nrclinonc.2017.14 Pantel, 2019, Liquid biopsy and minimal residual disease - latest advances and implications for cure, Nat. Rev. Clin. Oncol., 16, 409, 10.1038/s41571-019-0187-3 Wan, 2017, Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat. Rev. Cancer, 17, 223, 10.1038/nrc.2017.7 Corcoran, 2018, Application of cell-free DNA analysis to cancer treatment, N. Engl. J. Med., 379, 1754, 10.1056/NEJMra1706174